These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34264739)

  • 1. Validating the clinical relevance of alternative stimulant use treatment outcome measures by examining their association with 3-month follow-up outcomes.
    Miguel AQC; Smith CL; Burduli E; Roll JM; McPherson SM
    Exp Clin Psychopharmacol; 2021 Jun; 29(3):288-293. PubMed ID: 34264739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials.
    Amin-Esmaeili M; Farokhnia M; Susukida R; Leggio L; Johnson RM; Crum RM; Mojtabai R
    Addiction; 2024 May; 119(5):833-843. PubMed ID: 38197836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring the mediating role of baseline urinalysis results on demographic characteristics and stimulant use disorder treatment outcomes.
    Smith CL; Miguel AQ; Keever A; Bowden T; Burduli E; Roll J; McPherson SM
    J Subst Use Addict Treat; 2023 Aug; 151():208962. PubMed ID: 36801204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: a national drug abuse treatment clinical trials network study.
    Petry NM; Peirce JM; Stitzer ML; Blaine J; Roll JM; Cohen A; Obert J; Killeen T; Saladin ME; Cowell M; Kirby KC; Sterling R; Royer-Malvestuto C; Hamilton J; Booth RE; Macdonald M; Liebert M; Rader L; Burns R; DiMaria J; Copersino M; Stabile PQ; Kolodner K; Li R
    Arch Gen Psychiatry; 2005 Oct; 62(10):1148-56. PubMed ID: 16203960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lower-cost incentives on stimulant abstinence in methadone maintenance treatment: a National Drug Abuse Treatment Clinical Trials Network study.
    Peirce JM; Petry NM; Stitzer ML; Blaine J; Kellogg S; Satterfield F; Schwartz M; Krasnansky J; Pencer E; Silva-Vazquez L; Kirby KC; Royer-Malvestuto C; Roll JM; Cohen A; Copersino ML; Kolodner K; Li R
    Arch Gen Psychiatry; 2006 Feb; 63(2):201-8. PubMed ID: 16461864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda.
    Kiluk BD; Carroll KM; Duhig A; Falk DE; Kampman K; Lai S; Litten RZ; McCann DJ; Montoya ID; Preston KL; Skolnick P; Weisner C; Woody G; Chandler R; Detke MJ; Dunn K; Dworkin RH; Fertig J; Gewandter J; Moeller FG; Ramey T; Ryan M; Silverman K; Strain EC
    Drug Alcohol Depend; 2016 Jan; 158():1-7. PubMed ID: 26652899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of amphetamine use disorder and mortality among incident users of prescribed stimulant medications in the Veterans Administration.
    Westover AN; Nakonezny PA; Halm EA; Adinoff B
    Addiction; 2018 May; 113(5):857-867. PubMed ID: 29215762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psychosocial interventions for cannabis use disorder.
    Gates PJ; Sabioni P; Copeland J; Le Foll B; Gowing L
    Cochrane Database Syst Rev; 2016 May; 2016(5):CD005336. PubMed ID: 27149547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short and long-term improvements in psychiatric symptomatology to validate clinically meaningful treatment outcomes for cocaine use disorders.
    Miguel AQC; Kiluk BD; Babuscio TA; Nich C; Mari JJ; Carroll KM
    Drug Alcohol Depend; 2019 May; 198():126-132. PubMed ID: 30921648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of 12-Step Attendance and Participation for Individuals With Stimulant Use Disorders.
    Hatch-Maillette M; Wells EA; Doyle SR; Brigham GS; Daley D; DiCenzo J; Donovan D; Garrett S; Horigian VE; Jenkins L; Killeen T; Owens M; Perl HI
    J Subst Abuse Treat; 2016 Sep; 68():74-82. PubMed ID: 27431050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers.
    Winhusen TM; Brigham GS; Kropp F; Lindblad R; Gardin JG; Penn P; Hodgkins C; Kelly TM; Douaihy A; McCann M; Love LD; DeGravelles E; Bachrach K; Sonne SC; Hiott B; Haynes L; Sharma G; Lewis DF; VanVeldhuisen P; Theobald J; Ghitza U
    J Clin Psychiatry; 2014 Apr; 75(4):336-43. PubMed ID: 24345356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of prior stimulant treatment for attention-deficit/hyperactivity disorder on subsequent risk for cigarette smoking and alcohol and drug use disorders in adolescents.
    Wilens TE; Adamson J; Monuteaux MC; Faraone SV; Schillinger M; Westerberg D; Biederman J
    Arch Pediatr Adolesc Med; 2008 Oct; 162(10):916-21. PubMed ID: 18838643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of stimulant abuse treatment outcomes in severely mentally ill outpatients.
    Angelo FN; McDonell MG; Lewin MR; Srebnik D; Lowe J; Roll J; Ries R
    Drug Alcohol Depend; 2013 Jul; 131(1-2):162-5. PubMed ID: 23273776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness.
    McDonell MG; Srebnik D; Angelo F; McPherson S; Lowe JM; Sugar A; Short RA; Roll JM; Ries RK
    Am J Psychiatry; 2013 Jan; 170(1):94-101. PubMed ID: 23138961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term functioning to provide empirical support for the clinical relevance of treatment outcomes for methamphetamine use disorders.
    Miguel AQC; Smith CL; Burduli E; Roll JM; McPherson S
    J Subst Abuse Treat; 2021 May; 124():108291. PubMed ID: 33771286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of contingency management and cognitive-behavioral approaches for stimulant-dependent individuals.
    Rawson RA; McCann MJ; Flammino F; Shoptaw S; Miotto K; Reiber C; Ling W
    Addiction; 2006 Feb; 101(2):267-74. PubMed ID: 16445555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors and Outcomes of Twelve-Step Sponsorship of Stimulant Users: Secondary Analyses of a Multisite Randomized Clinical Trial.
    Wendt DC; Hallgren KA; Daley DC; Donovan DM
    J Stud Alcohol Drugs; 2017 Mar; 78(2):287-295. PubMed ID: 28317510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
    Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Examining Longitudinal Stimulant Use and Treatment Attendance as Parallel Outcomes in Two Contingency Management Randomized Clinical Trials.
    McPherson S; Brooks O; Barbosa-Leiker C; Lederhos C; Lamp A; Murphy S; Layton M; Roll J
    J Subst Abuse Treat; 2016 Feb; 61():18-25. PubMed ID: 26456717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.
    Siefried KJ; Acheson LS; Lintzeris N; Ezard N
    CNS Drugs; 2020 Apr; 34(4):337-365. PubMed ID: 32185696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.